Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Nov 15, 2021 12:43pm
166 Views
Post# 34127757

RE:RE:RE:RE:RE:Still Waiting for 1st Dosed Patient

RE:RE:RE:RE:RE:Still Waiting for 1st Dosed PatientHummmmmm,,,I expect the next announcement around financing will be a brokered placement at .42 cents with half warrants attached at some disrespectful price level like .90 cents...out for a minimum of 4 years. Time enuff incase they actually do get into the BoMll trial and have results within these 4 years. Hard to say,,yet,,,may take a few more years on top of that,,,,,cuz the team is way too busy in the back ground!!,,What ever they are doing?,,,we have been broke for the past two complete years feeding salaries with zero progress to show the market. Large dilution coming is written all over this play,,and the market knows it,,,,,Pinoccio can fool us retailers,,but he cant fool the market!!,,,the trading activity tells all!

<< Previous
Bullboard Posts
Next >>